NYSE · LLY
Eli Lilly and Company
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for LLY has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $5.38 | $5.48 | $5.30 | 3 |
| Dec 2026 | $10.46 | $11.46 | $9.90 | 4 |
| Mar 2027 | $9.70 | $9.70 | $9.70 | 1 |
| Jun 2027 | $10.40 | $10.40 | $10.40 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · RTTNews · The Motley Fool- Fintel · 1 h agoEli Lilly and Company Reports Q3 2026 Revenue of $24.4 billion and Updates Full-Year GuidanceEli Lilly and Company announced its financial results for the third quarter of 2026, reporting worldwide revenue of $24.4 billion, which represents an increase of 39% compared with Q3 2025. Revenue growth was driven by global consumer demand for Mounjaro and Zepbound, with Key Pr
- Zacks · 3 h agoLLY Stock Jumps as Q3 Earnings Beat Estimates, 2026 Sales View RaisedLilly's Q3 earnings and sales beat estimates, driven by Mounjaro and Zepbound, as the company raises its 2026 revenue outlook to $91-$92 billion.
- RTTNews · 3 h agoEli Lilly Reports 39% Q3 Revenue Growth, Raises 2026 Sales Outlook And Advances Drug Pipeline(RTTNews) – Eli Lilly and Company (LLY) reported higher third-quarter 2026 profit and revenue, driven primarily by strong demand for Mounjaro and Zepbound.
- Zacks · 3 h agoGDP, PCE, Jobless Claims and Q3 Earnings – Busy Morning!Headline PCE Price Index month over month reached +0.5%, in-line with expectations. Year over year, this came in at +3.6%.
- RTTNews · 4 h agoEli Lilly And Co. Q3 26 Earnings Conference Call At 10:00 AM ET(RTTNews) – Eli Lilly And Co. (LLY) will host a conference call at 10:00 AM ET on October 29, 2026, to discuss Q3 26 earnings results.
- RTTNews · 5 h agoLilly Q3 Profit Rises 16%; Lifts FY26 Sales View, Trims Adjusted Earnings Outlook(RTTNews) – Drugmaker Eli Lilly and Company (LLY) reported Thursday higher third-quarter profit and revenue, driven primarily by Mounjaro and Zepbound.
- Zacks · 5 h agoEli Lilly (LLY) Surpasses Q3 Earnings and Revenue EstimatesLilly (LLY) delivered earnings and revenue surprises of +39.03% and +10.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · 6 h agoEli Lilly And Co. Profit Climbs In Q3(RTTNews) – Eli Lilly And Co. (LLY) announced earnings for its third quarter that Increases, from last year
- The Motley Fool · 8 h agoCould Revolution Medicines Be a Millionaire-Maker Stock?Revolution Medicines' stock has soared over 9x in three years.
- RTTNews · 11 h agoOura Launches First Clinical Trial To Study GLP-1 Obesity Treatment Outcomes(RTTNews) – Oura (OURA) is expanding its healthcare research through a multi-year clinical trial with UC San Diego Health to examine how data from its smart ring may be associated with outcomes in people receiving GLP-1 medications or undergoing bariatric surgery for obesity.
- BNK Invest · Oct 28, 3:25 PM EDTNotable Wednesday Option Activity: ENPH, LLY, SNDKLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Enphase Energy Inc. (Symbol: ENPH), where a total volume of 64,106 contracts has been traded thus far today, a contract volume which is representative of approxi
- Zacks · Oct 28, 9:33 AM EDTHow Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3?Eli Lilly is expanding beyond GLP-1 drugs as neuroscience and immunology therapies fuel growth ahead of Q3 results, with Kisunla, Taltz and newer drugs in focus.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Eli Lilly and Company from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.